RIGA, OCTOBER 11 -12, 2013

MAIN PROGRAM

  • FRIDAY, 11 OCTOBER, 2013

    • 09:00 – 09:10 Welcome
      Gustavs Latkovskis, Chairman of the Baltic Atherosclerosis Congress,
      President-Elect of the Baltic Atherosclerosis Society
      Zita Kucinskiene, President of the Baltic Atherosclerosis Society

      SESSION 1

      Burden and pathobiology of atherosclerosis
      09:10 – 09:30  Burden of atherosclerotic diseases in the Baltic States. Vilnis Dzerve (Latvia)
      09:30 – 10:00  Understanding atherosclerosis: a historic perspective. Kristaps Zarins (USA)
      10:00 – 10:20  Current concepts of plaque instability and neoatherosclerosis.
      Andrejs Erglis (Latvia)

      10:20 – 10:40  New concepts derived from genome wide analyses. Siim Sober (Estonia)


      10:40
      – 11:00 Coffee break

      11:00 – 11:10 Welcome address
      Ingrida Circene, Minister of Health of Latvia
      Andrejs Erglis, President of the Latvian Society of Cardiology,
      Co-Chairman of the Baltic Atherosclerosis Congress

      SESSION 2
      Risk estimation for primary prevention
      11:10 – 11:40  Challenges of risk estimation in primary prevention. Zeljko Reiner (Croatia)
      11:40 – 12:00  Advantages and disadvantages of the risk prediction models.
      Karl Andersen (Iceland)

      12:00 – 12:20 
      Arterial markers of early atherosclerosis: clinical relevance and prognostic value. Ligita Ryliskyte (Lithuania)
      12:20 – 12:40  Novel imaging techniques of atherosclerosis hemodynamic assessment.
      Kristaps Zarins (USA)
      12:40 – 13:00  Are we ready to incorporate genes in risk estimation? Lithuanian way towards genomics of coronary heart disease. Ingrida Domarkiene (Lithuania)


      13:00 – 14:00 Lunch

      SESSION 3
      Management of dyslipidimias
      14:00 – 14:30  Familial hypercholesterolemia: cascade screening and clinical implications.
      G. Kees Hovingh (The Netherlands)
      14:30 – 14:50  LDL-C goals as the mainstay of prevention. Gustavs Latkovskis (Latvia)
      14:50 – 15:10  Statin side effects and safety. Rimvydas Slapikas (Lithuania)
      15:10 – 15:30  Do we care about Lp{a} and Lp-PLA2? Edwin Blumberg (USA)


      15:30 – 15:50 Coffee break

      SESSION 4
      Management of dyslipidemias
      15:50 – 16:20  Emerging therapies of dyslipidemias. G. Kees Hovingh (The Netherlands)
      16:20 – 16:40  Update on niacin and fibrates. Anu Hedman (Estonia)
      16:40 – 17:00  Omega-3 fatty acids. Edwin Blumberg (USA)
      17:00 – 17:20  Understanding HDL. Gustavs Latkovskis (Latvia)


      17:20 – 17:30  Elections of the board of the Baltic Atherosclerosis Society

      17:30               Welcome reception

  • SATURDAY, 12 OCTOBER, 2013


    • SESSION 5

      Lifestyle and traditional risk factors
      08:30 – 08:45  High-risk vs. population based strategy for cardiovascular prevention.
      Karl Andersen (Iceland)

      08:45 – 09:00  What is new in the European Hypertension Society 2013 guidelines?
      Margus Viigimaa (Estonia)
      09:00 – 09:15  Are all antihypertensive drugs equal? Gustavs Latkovskis (Latvia)
      09:15 – 09:30  Diabetes - targets and means, individualized approach. Valdis Pirags (Latvia)
      09:30 – 09:45  CVD risk factors perception and reality in different subpopulations – physicians, medical students, general population, elderly. Zeljko Reiner (Croatia)
      09:45 – 10:00  Evidence-based lifestyle changes and nutrition. Iveta Mintale (Latvia)


      10:30 – 10:50 Coffee break

      SESSION 6
      Novel risk factors and targets
      10:20 – 10:35  L-carnitine and atherosclerosis: a new potential therapeutic target.
      Maija Dambrova (Latvia)

      10:35 – 10:50  Cardiovascular risk and prevention in patients with chronic kidney disease. Marius Miglinas (Lithuania)
      10:50 – 11:05  Vitamin D, calcium metabolism and cardiovascular risk. 
      Virginijus Sapoka, Andrius Bleizgys (Lithuania)

      11:05 – 11:20  Thyroid dysfunction and cardiovascular disease. Anu Ambos (Estonia)
      11:20 – 11:35  Role of polyphenols in cardiovascular disease. Andrejs Erglis (Latvia)
      11:35 – 11:50  Why lycopene is beneficial against cardiovascular disease?
      Asta Mazeikiene (Lithuania)

      12:20 – 12:30 ADJOURN

       

      Download the Baltic Atherosclerosis Congress flyer here